Luye Pharma Group Overview
- Year Founded
-
1994
- Status
-
Public
- Employees
-
5,270
- Stock Symbol
-
02186
- Investments
-
8
- Share Price
-
$0.20
- (As of Friday Closing)
Luye Pharma Group General Information
Description
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
Contact Information
Website
www.luye.cnCorporate Office
- 22 Floor, Phase II, Gubei International Fortune Center
- 1438 Hongqiao Road, Changning District
- Shanghai
- China
Corporate Office
- 22 Floor, Phase II, Gubei International Fortune Center
- 1438 Hongqiao Road, Changning District
- Shanghai
- China
Luye Pharma Group Stock Performance
As of 13-Nov-2026, Luye Pharma Group’s stock price is $0.20. Its current market cap is $799M with 3.99B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.20 | $0.21 | $0.20 - $0.42 | $799M | 3.99B | 27.8M | $0.02 |
Luye Pharma Group Financials Summary
As of 30-Jun-2026, Luye Pharma Group has a trailing 12-month revenue of $876M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,641,276 | 2,093,924 | 1,610,336 | 2,186,169 |
| Revenue | 875,951 | 877,221 | 844,746 | 868,294 |
| EBITDA | 350,959 | 330,206 | 293,674 | 277,074 |
| Net Income | 99,517 | 86,041 | 65,764 | 75,281 |
| Total Assets | 5,132,941 | 4,691,546 | 4,056,410 | 3,596,015 |
| Total Debt | 1,764,225 | 1,345,961 | 1,413,824 | 1,188,380 |
Luye Pharma Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Luye Pharma Group Comparisons
Industry
Financing
Details
Luye Pharma Group Competitors (3)
One of Luye Pharma Group’s 3 competitors is Huipusen, a Corporation company based in Haikou, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Huipusen | Corporation | Haikou, China | ||||
| CANbridge Pharma | Formerly VC-backed | Beijing, China | ||||
| Qilu Pharmaceutical | Corporation | Jinan, China |
Luye Pharma Group Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Luye Pharma Group Patents
Luye Pharma Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025237418-A1 | Salt and crystal form of cdk2 inhibitor, and preparation method therefor and use thereof | Pending | 17-May-2024 | ||
| AU-2024404970-A1 | Salt form of taar1 ligand agonist, crystal form, preparation method, and use | Pending | 22-Dec-2023 | ||
| EP-4831181-A1 | Salt form of taar1 ligand agonist, crystal form, preparation method, and use | Pending | 22-Dec-2023 | ||
| WO-2025131045-A1 | Salt form of taar1 ligand agonist, crystal form, preparation method, and use | Inactive | 22-Dec-2023 | ||
| AU-2024395966-A1 | Crystal form of gaba a receptor modulator, preparation method therefor and use thereof | Pending | 08-Dec-2023 | C07J43/00 |
Luye Pharma Group Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Luye Pharma Group Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Luye Pharma Group Investments & Acquisitions (8)
Luye Pharma Group’s most recent deal was a Corporate with Boan Biotech for . The deal was made on 23-Jun-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Boan Biotech | 23-Jun-2020 | Corporate | Drug Discovery | ||
| Boan Biotech | 01-May-2019 | Merger/Acquisition | Drug Discovery | ||
| Bayer (Global Rights To Hormonal Contraceptive) | 06-Aug-2018 | Corporate Asset Purchase | Pharmaceuticals | ||
| Seroquel XR | 27-May-2018 | Corporate Asset Purchase | Buildings and Property | ||
| Exicure | 06-Nov-2017 | Later Stage VC | Drug Discovery |
Luye Pharma Group ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.03 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Luye Pharma Group Exits (5)
Luye Pharma Group’s most recent exit was on 23-Jun-2020 from Boan Biotech. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Boan Biotech | 23-Jun-2020 | Completed |
|
||
| Boan Biotech | 01-May-2019 | Completed |
|
||
| Exicure | 06-Nov-2017 | Completed |
|
||
| A-Bio Pharma | 02-Aug-2010 | Completed |
|
||
| LifeTech Jiuzhoutong New (Special Drug) | 23-Oct-2006 | Merger/Acquisition | Completed |
Luye Pharma Group Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Boan Biotech | Yantai, China | 2013 |
Luye Pharma Group FAQs
-
When was Luye Pharma Group founded?
Luye Pharma Group was founded in 1994.
-
Where is Luye Pharma Group headquartered?
Luye Pharma Group is headquartered in Shanghai, China.
-
What is the size of Luye Pharma Group?
Luye Pharma Group has 5,270 total employees.
-
What industry is Luye Pharma Group in?
Luye Pharma Group’s primary industry is Pharmaceuticals.
-
Is Luye Pharma Group a private or public company?
Luye Pharma Group is a Public company.
-
What is Luye Pharma Group’s stock symbol?
The ticker symbol for Luye Pharma Group is 02186.
-
What is the current stock price of Luye Pharma Group?
As of 13-Nov-2026 the stock price of Luye Pharma Group is $0.20.
-
What is the current market cap of Luye Pharma Group?
The current market capitalization of Luye Pharma Group is $799M.
-
What is Luye Pharma Group’s current revenue?
The trailing twelve month revenue for Luye Pharma Group is $876M.
-
Who are Luye Pharma Group’s competitors?
Huipusen, CANbridge Pharma, and Qilu Pharmaceutical are competitors of Luye Pharma Group.
-
What is Luye Pharma Group’s annual earnings per share (EPS)?
Luye Pharma Group’s EPS for 12 months was $0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
